InvestorsHub Logo
Followers 6
Posts 136
Boards Moderated 0
Alias Born 05/08/2014

Re: ou71764 post# 11733

Thursday, 05/29/2014 12:52:27 PM

Thursday, May 29, 2014 12:52:27 PM

Post# of 725428
I actually believe mis-interpretation by investors is a far larger and more likely risk than anything LP ends up sharing for DCVax-L. The strategy of pre-fielding questions in this kind of hostile environment is perfect as it focuses the attention of everyone on the subject at hand, which is DCVax-Direct.

There are already too many folks that would spin any kind of information (rumors, hypothesis, facts, or other) in a misleading manner (both positive and negative). Regularly reading this board already reveals a number of these players.

Waiting until for a concrete recommendation from the DMC is, IMO, the best course of action that can be taken by NWBO. That is a data point that no one can question.

Any other type of action will divert NWBO attention from its course of guiding their drug platform through the many regulations of the FDA and continuously improving the already top notch manufacturing operations that is currently in place.

I am very satisfied with how NWBO is proceeding with DCVax-L in terms of information. I want nothing from the company regarding status until the DMC is ready to share a concrete recommendation OR the FDA grants a surprise AA.

If the DMC recommendation is negative (which I do not believe at all) then I failed in my own due diligence and need to re-visit my research process and procedures to see where improvements are needed.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News